Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136471 | 1.00 | CYP1A2 (0.69) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL664978 | 1.00 | CYP1A2 (0.69) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL28296028 | 1.00 | CYP1A2 (0.69) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL8710704 | 0.98 | CYP1A2 (0.71) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL28238797 | 0.98 | CYP1A2 (0.71) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL28237732 | 0.98 | CYP1A2 (0.71) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL5988542 | 0.92 | CYP1A2 (0.62) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL5105796 | 0.92 | CYP1A2 (0.62) | CYP1A2ALDH1A1L3MBTL1PPARGCHRM5 | |
| SCHEMBL9862755 | 0.88 | CYP1A2 (0.55) | CYP1A2PPARGPRKCA | |
| SCHEMBL28363554 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109832623-A | A kind of nutrition fermented food | 臻味之(烟台)食品科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-20040225135-A1 | Method of producing optically active lactone compound | KYUSHA UNIVERSITY (JP) | 2004-11-11 | — | — | US | claimed |
| US-6784302-B2 | HIGHER ENANTIOMERIC EXCESS BY USING A SPECIFIED ZIRCONIUM (SALEN) COMPLEX AS CATALYST TO CONDUCT A BAEYER-VILLIGER REACTION OF A CYCLIC KETONE; OXIDATION USING A HYDROGEN PEROXIDE OXIDIZER TO PRODUCE CYCLIC ESTERS | KYUSHU UNIVERSITY (JP) | 2004-08-31 | — | — | US | claimed |
| EP-1449840-A1 | Method of producing optically active lactone compound | Kyushu University (JP) | 2004-08-25 | — | — | EP | claimed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | claimed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | claimed |
| EP-1352908-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2003-10-15 | — | — | EP | claimed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | claimed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | claimed |
| CN-109832623-A | A kind of nutrition fermented food | 臻味之(烟台)食品科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20040225135-A1 | Method of producing optically active lactone compound | KYUSHA UNIVERSITY (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6784302-B2 | HIGHER ENANTIOMERIC EXCESS BY USING A SPECIFIED ZIRCONIUM (SALEN) COMPLEX AS CATALYST TO CONDUCT A BAEYER-VILLIGER REACTION OF A CYCLIC KETONE; OXIDATION USING A HYDROGEN PEROXIDE OXIDIZER TO PRODUCE CYCLIC ESTERS | KYUSHU UNIVERSITY (JP) | 2004-08-31 | — | — | US | disclosed |
| EP-1449840-A1 | Method of producing optically active lactone compound | Kyushu University (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1352908-A1 | Method of producing optically active lactone compound and complex used in the method | KYUSHU UNIVERSITY (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010152-A1 | Method of producing optically active lactone compound and complex used in the method | CYC1, CYP11B1, CYP17A1 | CYP1A2 159/4885ALDH1A1 338/4885L3MBTL1 4112/4885 |
| US-20040225135-A1 | Method of producing optically active lactone compound | PPOX, CYP11B1, CYP17A1 | CYP1A2 519/4885ALDH1A1 1491/4885L3MBTL1 3380/4885 |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | SOD1, OAT, SOD3 | CYP1A2 413/4885ALDH1A1 691/4885L3MBTL1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.